Development of novel DNA gyrase B inhibitors is an important field of antibacterial drug discovery whose aim is to introduce a more effective representative of this mechanistic class into the clinic. In the present study, two new series of Escherichia coli DNA gyrase inhibitors bearing the 4,5-dibromopyrrolamide moiety have been designed and synthesized. 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazole-2,6-diamine derivatives inhibited E. coli DNA gyrase in the submicromolar to low micromolar range (IC 50 values between 0.891 and 10.4 µM). Their "ring-opened" analogues, based on the 2-(2-aminothiazol-4-yl)acetic acid scaffold, displayed weaker DNA gyrase inhibition with IC 50 values between 15.9 and 169 µM. Molecular docking experiments were conducted to study the binding modes of inhibitors.
Introduction
Antibacterial drug resistance, especially that of 'ESKAPE' organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and Enterobacter spp.), is a growing threat to human health, not only in hospitals but in the community in general [1] . Therefore, continuous discovery and development of new antibacterial agents that avoid the existing resistance mechanisms is of great importance to increase the number of drug candidates in the pipeline for treating these serious, lifethreatening infections.
DNA gyrase is a well-established and validated target for antibacterial drug discovery.
It offers opportunities for the development of drugs that could avoid some of the existing resistance mechanisms. It catalyzes changes in DNA topology during replication by introducing negative supercoils. It is a heterotetrameric enzyme consisting of two GyrA subunits, which are involved in cleavage and reunion of the DNA substrate, and two GyrB subunits that, by hydrolysis of ATP, provide energy for the supercoiling reaction of GyrA.
Topoisomerase IV, which is involved in decatenation of daughter DNA following DNA replication, is structurally similar to DNA gyrase, being composed of two ParC and two ParE subunits that are homologous to GyrA and GyrB, respectively [2] .
The structural similarity of DNA gyrase and topoisomerase IV provides the opportunity for dual targeting in most bacteria, which prolongs the onset of resistance, making these two enzymes attractive targets for antibacterial drug discovery [3, 4] . The GyrA subunits are targets of the clinically important class of antibacterial drugs, the fluoroquinolones, which stabilize the complex between DNA gyrase and DNA [5] . The increasing level of resistance to fluoroquinolones limits their therapeutic use [6] and stimulates the search either for novel structural classes of inhibitors targeting GyrA or for development of inhibitors of the GyrB ATPase activity [4, 7, 8] . Novobiocin, an 4 aminocoumarin antibiotic, remains the first and still the only, example of GyrB inhibitor that has been used in therapy, primarily for infections caused by Gram positive bacterial strains.
Its use declined during the 1960s and early 1970s following the introduction of penicillinasestable penicillins and the first generation of cephalosporins, and was eventually withdrawn from the market [4] . Despite extensive efforts to develop a new representative of this mechanistic class, no GyrB inhibitor has progressed beyond phase 1 clinical trials [4] . Several structural classes of GyrB and/or ParE inhibitors, such as cyclothialidines [9] , ethylureas [10] [11] [12] [13] [14] , azaindoles [15] , and pyrrolamides [16] [17] [18] , were investigated in the past decades by the pharmaceutical industry. The majority of these GyrB and/or ParE inhibitors possess potent enzyme inhibitory activity and antibacterial activity, but mainly against Gram positive strains [4] . In contrast, there are few examples of GyrB/ParE inhibitors displaying anti-Gram negative activity, such as pyrrolopyrimidines [19] and pyrimidinoindoles [20] . DNA gyrase inhibitors have been discovered by academic research groups, for example by virtual screening [21] [22] [23] and by structure-based design of marine alkaloid analogues [24, 25] .
Although many antibacterial drug discovery projects in the pharmaceutical industry were recently terminated, the knowledge gathered over more than 50 years of research directed towards ATPase inhibitors of DNA gyrase and topoisomerase IV provides an excellent foundation for further research to finally introduce a new and effective representative of this mechanistic class in antibacterial therapy [4] .
We have recently designed several structural classes of analogues of marine alkaloids based on clathrodin, hymenidin and oroidin, isolated from sponges of the genus Agelas, and evaluated their voltage-gated sodium channel modulatory activity [26] [27] [28] [29] , inhibition of biofilm formation [30] , antimicrobial activity [31] , and pro-apoptotic activity in HepG2 and THP-1 cell lines [32] . The similarity of oroidin and its analogues to the known pyrrolamidebased inhibitors [17, 18] stimulated us to evaluate selected oroidin analogues from our library 5 for E. coli DNA gyrase inhibition. Optimization of the hit compounds [24] and design of novel 4,5-dibromopyrrolamide derivatives [25] resulted in potent DNA gyrase inhibitors exhibiting IC 50 values in the low nanomolar range, but possessing weak antibacterial activity.
The X-ray crystal structure of 4,5-dibromopyrrolamide-based inhibitor in complex with E. coli DNA gyrase subunit B was solved, which confirmed the assumed binding mode of inhibitor to the ATP-binding site of DNA gyrase [25] . The pyrrolamide moiety was found to occupy the same binding pocket of the E. coli GyrB ATP-binding site as that observed for other pyrrolamide-based DNA gyrase inhibitors, such as natural antibiotics clorobiocin [33] and kibdelomycin [34] , and some described synthetic inhibitors [17, 18] (Figure 1 ). We describe here the design and synthesis of a novel series of 4,5-dibromopyrrolamides and the evaluation of their E. coli DNA gyrase inhibition as well as their antibacterial activity against selected Gram positive and Gram negative bacterial strains. 
Results and discussion

Design
X-Ray crystal structure of the 4,5-dibromopyrrolamide-based inhibitor I in the ATPbinding site of E. coli DNA gyrase revealed three hydrogen bonds formed between the 6 enzyme and the pyrrolamide moiety of inhibitor [25] . A hydrogen bond is seen between a pyrrole NH group and the Asp73 side chain, while a second hydrogen bond is formed between an adjacent carbonyl group and a structurally conserved water molecule that is in contact with the Asp73 side chain ( Figure 2 ) [25] . With this conserved binding motif of adjacent hydrogen bond donor/acceptor groups, GyrB inhibitors mimic the binding of ATP [8] . The NH of the amide group is additionally bridged by a water molecule to the side chain of Thr365 ( Figure 2 ). The formation of several hydrophobic interactions between the dibromo substituted pyrrole moiety and the protein is crucial for achieving potent E. coli DNA gyrase inhibition, since 4-bromopyrrole, 4,5-dichloropyrrole and indole derivatives displayed weaker inhibition of the enzyme [24, 25] . In this new series, the 4,5-dibromopyrrolamide moiety has thus been retained. To further explore the structure-activity relationship of the 4,5,6,7tetrahydrobenzo[1,2-d]thiazole-2,6-diamine derivatives we synthesized compounds in which the 4,5-dibromopyrrole-2-carbonyl moiety is attached to the amino group at position 2, instead of that at position 6, resulting in the "reversed" type III analogues ( Figure 3 ) of the parent compounds (compound II and its analogues [24] , Figure 3 ). Additional substituents designed to target the Arg76/Arg136 side chain were then introduced at the 6-amino group ( Figure 3 ). In addition, a series of 2-(2-aminothiazol-4-yl)acetic acid derivatives (type IV analogues, Figure 3 ) were designed and synthesized. These so-called "ring-opened" compounds are more flexible than type III compounds and possess a smaller central scaffold, and thereby offering the opportunity for the introduction of larger substituents for potential interaction with Arg76/Arg136. The design of all these compounds was supported by 
Chemistry
The designed 4,5,6,7-tetrahydrobenzo [1,2-d] were synthesized according to the reported procedure [24, 35] . In the first step, the amino group at position 6 was protected as a tert-butylcarbamate using di-tert-butyl dicarbonate in tetrahydrofuran to yield (R)-2 and (S)-2. The amino group at position 2 of (R)-2 and (S)-2 was then acylated with 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethanone in N,N- (9) was first esterified with methanol to give 10 and the amino group at position 2 of the thiazole moiety of 10 then acylated by 2,2,2trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethanone, as described above, to give compound 11.
Hydrolysis of the methyl ester 11 resulted in carboxylic acid 12, which was coupled with either glycine methyl ester hydrochloride to give 13 or substituted aniline derivatives 15-18 Molecular docking experiments using FlexX [36, 37] , as available in LeadIT (BioSolveIT GmbH) [38] , were conducted to study the binding modes of E. coli DNA gyrase inhibitors (R)-5, (S)-5, (S)-6, (R)-7, (S)-7 and (S)-8. We used our already described and validated docking protocol [24] using the high-resolution crystal structure of the 4,5'bithiazole inhibitor in complex with E. coli DNA gyrase (PDB entry: 4DUH) as the target protein [22] . The obtained docking poses and scoring function scores cannot explain the observed differences in binding affinities. All tested inhibitors are predicted to form two hydrogen bonds in the pyrrolamide-binding pocket, one direct and one bridged by a conserved water molecule to Asp73 side chain ( Figure 4 ). Moreover, docking predicts formation of additional hydrogen bonds with Arg76 and/or Arg136 side chains, but the binding modes suggest that there is no interaction between a salt bridge made by Glu50-Arg76 residues and the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole ring of inhibitors ( Figure 4 ). This could explain why oxalic acid-based compound (S)-7 (IC 50 = 1.12 µM) is less potent that its counterpart II ( Figure 3 , IC 50 = 0.058 µM, while its benzothiazole-based analogue, in which such interaction is still possible, was shown to possess almost equipotent activity as compound II [39] . growth inhibition less than 50% for all compounds) ( Table 1) . There are several possible explanations for the observed lack of correlation between in vitro enzyme inhibition and antibacterial activity against selected bacterial strains. Firstly, the enzymatic activity could be too low (IC 50 values between 0.891 and 10.4 µM) to result in inhibition of bacterial growth of
Gram negative E. coli, since subnanomolar K i values against cytoplasmic targets could be required to generate sufficient antibacterial potency on Gram negative bacteria [20] .
Pyrrolamide-based type II analogues (compound II and its analogues, Figure 3 ) that displayed potent E. coli DNA gyrase inhibition in the low nanomolar range were also devoid of antibacterial activity against Gram negative strains [24] . Secondly, type II compounds [24] and pyrrolamides presented in Figure 1 were shown to possess more potent antibacterial activity against the ΔtolC E. coli strain, which lacks the outer membrane tolC efflux pump, than against the wild-type E. coli strain [16, 17] . Therefore, active efflux of the compounds from bacterial cells could be the second reason for the inactivity of pyrrolamide-based DNA gyrase inhibitors including compounds (R)-5, (S)-5, (S)-6, (R)-7, (S)-7 and (S)-8 in vitro.
We assume that the 4,5-dibromopyrrole moiety is too bulky to occupy the hydrophobic pocket of S. aureus DNA gyrase [24] , resulting in weak inhibition of S. aureus DNA gyrase by 4,5-dibromopyrrolamide-based compounds and, hence, in the weak antibacterial activity against Gram positive S. aureus [24, 25] . To evaluate this hypothesis, compounds (S)-7 and (S)-8 were tested for S. aureus DNA gyrase inhibition and showed weak inhibition with enzyme residual activities of 77% and 69% at 10 µM, respectively, which is probably too weak inhibition to result in antibacterial activity. 13 2-(2-Aminothiazol-4-yl)acetic acids 11-20 (Table 2) were designed as ring-opened analogues of the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazoles ( Figure 3 ). In the first step, compounds 13 and 14, which by their length mimic the structures of 5 and 7, were prepared.
2-(2-Aminothiazol-4-yl)acetic acids
Their E. coli DNA gyrase inhibitory activity, with IC 50 values of 170 µM for glycine ester derivative 13 and 16 µM for its carboxylic acid 14, are weaker than those for 5 and 7.
However, docking studies suggest similar binding modes for 14 ( Figure 5 inhibitory activity is probably still too weak to result in potent antibacterial activity ( Table 2 ). 
General procedure B. Synthesis of compounds (R)-3 and (S)-3
A solution of (S)-or (R)-2 (1 mmol) and Na 2 CO 3 (1 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 15 min. Then 2,2,2-trichloro-1-(4,5-dibromo-1Hpyrrol-2-yl)ethan-1-one (1.1 mmol) was added and the mixture stirred at 80 °C overnight.
Solvent was removed under reduced pressure and the crude product dissolved in ethyl acetate (10 mL). Organic phase was successively washed with 10% citric acid (10 mL), saturated aqueous NaHCO 3 solution (10 mL) and brine (10 mL 
General procedure C. Synthesis of compounds (R)-4 and (S)-4
Methanol (10 mL) was cooled on an ice bath and then acetyl chloride (10 mmol) was added dropwise. The mixture was stirred at 0 °C for 30 min and then solution of (R)-3 or (S)-3
(1 mmol) in methanol (10 mL) was added. Reaction mixture was stirred at 0 °C for 1 h and then at room temperature overnight. 
General procedure D. Synthesis of compounds (S)-5, (R)-5 and (S)-6
To a solution of amine (1 mmol ) 
General procedure E. Synthesis of compounds (S)-7, (R)-7 and (S)-8
To a solution of ester (1 mmol) in methanol (5 mL 
Molecular modeling 4.4.1. Ligand and protein preparation
Three-dimensional models of designed compounds were built in ChemBio3D Ultra 13.0 [42] . Their geometries were optimized using MMFF94 [43] force field and partial atomic charges were added. Energy was minimized until the gradient value was smaller than 0.001 kcal/(mol Å). The optimized structure was further refined with GAMESS interface in ChemBio3D Ultra 13.0 using the semiempirical PM3 method, QA optimization algorithm and Gasteiger Hückel charges for all atoms for 100 steps [42] . Molecular docking calculations were performed using FlexX [36, 37] , as available in LeadIT [38] , running on four octal core AMD Opteron CPU processors, 16 GB RAM, two 750 GB hard drives, running 64-bit Scientific Linux 6.0. Receptor was prepared in a LeadIT graphical user interface using the Receptor wizard. Amino acid residues within a radius of 7 Å around the ligand from the X-ray structure (PDB entry: 4DUH [22] ) were defined as the binding site. Hydrogen atoms were added to the binding site residues and correct tautomers and protonation states were assigned.
Water molecules, except HOH614, and the ligand were deleted from the crystal structure.
Validation of the docking protocol and ligand docking
The FlexX molecular docking program, as available in LeadIT [38] , was used for ligand docking. A hybrid algorithm (enthalpy and entropy driven ligand binding) was used to place the 'base fragment'. The maximum number of solutions per iteration and the maximum number of solutions per fragmentation parameter values were increased to 1000, while other parameters were set at their default values.
In order to validate our docking protocol, crystal structure ligand was docked into the defined ATP-binding site of E. coli GyrB using the above described docking parameters. The protocol was able to reproduce the binding of the crystal structure ligand with an RMSD value of 1.2 Å, which highlights the docking protocol as suitable for binding mode studies of the designed DNA gyrase inhibitors that were docked using the same settings as used for docking protocol validation. Proposed binding modes and scoring function scores of the top five highest scored docking poses per ligand were evaluated and the highest ranked binding pose was used for graphical representation in PyMOL [40] .
